US-based biotechnology company FibroGen announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.

To support the move to a larger office facility in the Greater Toronto Area, Ontario, AstraZeneca plans to invest $570 million in Canada, creating more than 700 jobs.

Anglo-Swedish drugmaker AstraZeneca plans to invest $3.5 billion in the US to expand the company’s research and manufacturing footprint by the end of 2026.

In a move to enhance global supply of its antibody drug conjugates (ADCs) portfolio, AstraZeneca intends to build a $1.5 billion facility in Singapore for the...

AstraZeneca has agreed to acquire Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

Britain's AstraZeneca is to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases, more than $1...

AstraZeneca, whose CEO Pascal Soriot has been critical of the UK business environment for the life sciences industry in the past, wants to invest a large sum at its...

Within a few days, Anglo-Swedish drugmaker AstraZeneca has completed the acquisitions of Gracell Biotechnologies and Icosavax. Both transactions were announced in...